(ALAB) Astera Labs - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US04626A1034
Stock: Semiconductor Chips, Connectivity Solutions, Software Suite, Data Centers
Total Rating 59
Risk 39
Buy Signal -0.54
| Risk 5d forecast | |
|---|---|
| Volatility | 91.9% |
| Relative Tail Risk | -11.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.10 |
| Alpha | 34.83 |
| Character TTM | |
|---|---|
| Beta | 2.776 |
| Beta Downside | 1.675 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.69% |
| CAGR/Max DD | 0.63 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 98.3607
Technicals: volatileDescription: ALAB Astera Labs March 05, 2026
Astera Labs, Inc. (ALAB) designs and sells semiconductor solutions for cloud and AI infrastructure. The companys products include high-speed, mixed-signal connectivity chips that integrate microcontrollers and sensors. The semiconductor industry is a foundational component of the global technology economy.
ALAB also offers COSMOS, a software suite for managing and optimizing connectivity resources at cloud-scale. This business model combines hardware and software to provide comprehensive solutions. Their product portfolio includes PCIe/CXL retimers, Ethernet cable modules, CXL memory controllers, and smart fabric switches.
The company serves hyperscalers and original equipment manufacturers (OEMs). Consider exploring ValueRay for deeper insights into ALABs market position and financial performance.
Headlines to watch out for
AI infrastructure spending fuels demand for connectivity solutions | Hyperscaler adoption drives revenue growth | Semiconductor supply chain disruptions impact production | CXL technology advancements expand market opportunity
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 219.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 8.68 > 1.0 |
| NWC/Revenue: 144.2% < 20% (prev 233.8%; Δ -89.62% < -1%) |
| CFO/TA 0.21 > 3% & CFO 319.3m > Net Income 219.1m |
| Net Debt (-132.5m) to EBITDA (203.7m): -0.65 < 3 |
| Current Ratio: 10.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (181.2m) vs 12m ago 2.04% < -2% |
| Gross Margin: 75.69% > 18% (prev 0.76%; Δ 7492 % > 0.5%) |
| Asset Turnover: 65.93% > 50% (prev 37.58%; Δ 28.34% > 0%) |
| Interest Coverage Ratio: -9.23 > 6 (EBITDA TTM 203.7m / Interest Expense TTM -21.3m) |
Altman Z'' 6.40
| A: 0.80 (Total Current Assets 1.36b - Total Current Liabilities 133.0m) / Total Assets 1.53b |
| B: 0.01 (Retained Earnings 10.3m / Total Assets 1.53b) |
| C: 0.15 (EBIT TTM 196.8m / Avg Total Assets 1.29b) |
| D: 0.09 (Book Value of Equity 14.7m / Total Liabilities 168.2m) |
| Altman-Z'' Score: 6.40 = AAA |
Beneish M 1.00
| DSRI: 1.00 (Receivables 83.2m/38.8m, Revenue 852.5m/396.3m) |
| GMI: 1.01 (GM 75.69% / 76.38%) |
| AQI: 9.11 (AQ_t 0.05 / AQ_t-1 0.01) |
| SGI: 2.15 (Revenue 852.5m / 396.3m) |
| TATA: -0.07 (NI 219.1m - CFO 319.3m) / TA 1.53b) |
| Beneish M-Score: 2.54 (Cap -4..+1) = D |
What is the price of ALAB shares?
As of March 08, 2026, the stock is trading at USD 119.20 with a total of 4,189,262 shares traded.
Over the past week, the price has changed by +0.31%, over one month by -29.82%, over three months by -32.17% and over the past year by +87.75%.
Over the past week, the price has changed by +0.31%, over one month by -29.82%, over three months by -32.17% and over the past year by +87.75%.
Is ALAB a buy, sell or hold?
Astera Labs has received a consensus analysts rating of 4.47.
Therefore, it is recommended to buy ALAB.
- StrongBuy: 9
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 206.8 | 73.4% |
| Analysts Target Price | 206.8 | 73.4% |
ALAB Fundamental Data Overview March 07, 2026
P/E Trailing = 98.3607
P/E Forward = 48.3092
P/S = 23.9591
P/B = 14.2012
Revenue TTM = 852.5m USD
EBIT TTM = 196.8m USD
EBITDA TTM = 203.7m USD
Long Term Debt = 4.15m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.44m USD (from shortTermDebt, two quarters ago)
Debt = 35.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -132.5m USD (from netDebt column, last quarter)
Enterprise Value = 19.27b USD (20.43b + Debt 35.1m - CCE 1.19b)
Interest Coverage Ratio = -9.23 (Ebit TTM 196.8m / Interest Expense TTM -21.3m)
EV/FCF = 68.40x (Enterprise Value 19.27b / FCF TTM 281.8m)
FCF Yield = 1.46% (FCF TTM 281.8m / Enterprise Value 19.27b)
FCF Margin = 33.05% (FCF TTM 281.8m / Revenue TTM 852.5m)
Net Margin = 25.70% (Net Income TTM 219.1m / Revenue TTM 852.5m)
Gross Margin = 75.69% ((Revenue TTM 852.5m - Cost of Revenue TTM 207.3m) / Revenue TTM)
Gross Margin QoQ = 75.57% (prev 76.25%)
Tobins Q-Ratio = 12.58 (Enterprise Value 19.27b / Total Assets 1.53b)
Interest Expense / Debt = -60.65% (Interest Expense -21.3m / Debt 35.1m)
Taxrate = 43.00% (33.9m / 78.9m)
NOPAT = 112.2m (EBIT 196.8m * (1 - 43.00%))
Current Ratio = 10.24 (Total Current Assets 1.36b / Total Current Liabilities 133.0m)
Debt / Equity = 0.03 (Debt 35.1m / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = -0.65 (Net Debt -132.5m / EBITDA 203.7m)
Debt / FCF = -0.47 (Net Debt -132.5m / FCF TTM 281.8m)
Total Stockholder Equity = 1.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.95% (Net Income 219.1m / Total Assets 1.53b)
RoE = 18.21% (Net Income TTM 219.1m / Total Stockholder Equity 1.20b)
RoCE = 16.30% (EBIT 196.8m / Capital Employed (Equity 1.20b + L.T.Debt 4.15m))
RoIC = 9.33% (NOPAT 112.2m / Invested Capital 1.20b)
WACC = 16.12% (E(20.43b)/V(20.46b) * Re(16.15%) + (debt cost/tax rate unavailable))
Discount Rate = 16.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.00%
[DCF] Terminal Value 59.20% ; FCFF base≈210.0m ; Y1≈259.1m ; Y5≈441.2m
[DCF] Fair Price = 16.92 (EV 2.75b - Net Debt -132.5m = Equity 2.88b / Shares 170.2m; r=16.12% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 89.15 | EPS CAGR: 119.8% | SUE: 1.27 | # QB: 3
Revenue Correlation: 92.05 | Revenue CAGR: 116.2% | SUE: 3.44 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.55 | Chg7d=+0.001 | Chg30d=+0.013 | Revisions Net=+5 | Analysts=20
EPS current Year (2026-12-31): EPS=2.46 | Chg7d=+0.010 | Chg30d=+0.088 | Revisions Net=+9 | Growth EPS=+34.0% | Growth Revenue=+58.1%
EPS next Year (2027-12-31): EPS=3.52 | Chg7d=+0.031 | Chg30d=+0.268 | Revisions Net=+9 | Growth EPS=+42.9% | Growth Revenue=+38.0%
[Analyst] Revisions Ratio: +0.29 (11 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 15.1% (Discount Rate 16.1% - Earnings Yield 1.0%)
[Growth] Growth Spread = +45.8% (Analyst 60.9% - Implied 15.1%)
P/E Forward = 48.3092
P/S = 23.9591
P/B = 14.2012
Revenue TTM = 852.5m USD
EBIT TTM = 196.8m USD
EBITDA TTM = 203.7m USD
Long Term Debt = 4.15m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.44m USD (from shortTermDebt, two quarters ago)
Debt = 35.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -132.5m USD (from netDebt column, last quarter)
Enterprise Value = 19.27b USD (20.43b + Debt 35.1m - CCE 1.19b)
Interest Coverage Ratio = -9.23 (Ebit TTM 196.8m / Interest Expense TTM -21.3m)
EV/FCF = 68.40x (Enterprise Value 19.27b / FCF TTM 281.8m)
FCF Yield = 1.46% (FCF TTM 281.8m / Enterprise Value 19.27b)
FCF Margin = 33.05% (FCF TTM 281.8m / Revenue TTM 852.5m)
Net Margin = 25.70% (Net Income TTM 219.1m / Revenue TTM 852.5m)
Gross Margin = 75.69% ((Revenue TTM 852.5m - Cost of Revenue TTM 207.3m) / Revenue TTM)
Gross Margin QoQ = 75.57% (prev 76.25%)
Tobins Q-Ratio = 12.58 (Enterprise Value 19.27b / Total Assets 1.53b)
Interest Expense / Debt = -60.65% (Interest Expense -21.3m / Debt 35.1m)
Taxrate = 43.00% (33.9m / 78.9m)
NOPAT = 112.2m (EBIT 196.8m * (1 - 43.00%))
Current Ratio = 10.24 (Total Current Assets 1.36b / Total Current Liabilities 133.0m)
Debt / Equity = 0.03 (Debt 35.1m / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = -0.65 (Net Debt -132.5m / EBITDA 203.7m)
Debt / FCF = -0.47 (Net Debt -132.5m / FCF TTM 281.8m)
Total Stockholder Equity = 1.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.95% (Net Income 219.1m / Total Assets 1.53b)
RoE = 18.21% (Net Income TTM 219.1m / Total Stockholder Equity 1.20b)
RoCE = 16.30% (EBIT 196.8m / Capital Employed (Equity 1.20b + L.T.Debt 4.15m))
RoIC = 9.33% (NOPAT 112.2m / Invested Capital 1.20b)
WACC = 16.12% (E(20.43b)/V(20.46b) * Re(16.15%) + (debt cost/tax rate unavailable))
Discount Rate = 16.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.00%
[DCF] Terminal Value 59.20% ; FCFF base≈210.0m ; Y1≈259.1m ; Y5≈441.2m
[DCF] Fair Price = 16.92 (EV 2.75b - Net Debt -132.5m = Equity 2.88b / Shares 170.2m; r=16.12% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 89.15 | EPS CAGR: 119.8% | SUE: 1.27 | # QB: 3
Revenue Correlation: 92.05 | Revenue CAGR: 116.2% | SUE: 3.44 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.55 | Chg7d=+0.001 | Chg30d=+0.013 | Revisions Net=+5 | Analysts=20
EPS current Year (2026-12-31): EPS=2.46 | Chg7d=+0.010 | Chg30d=+0.088 | Revisions Net=+9 | Growth EPS=+34.0% | Growth Revenue=+58.1%
EPS next Year (2027-12-31): EPS=3.52 | Chg7d=+0.031 | Chg30d=+0.268 | Revisions Net=+9 | Growth EPS=+42.9% | Growth Revenue=+38.0%
[Analyst] Revisions Ratio: +0.29 (11 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 15.1% (Discount Rate 16.1% - Earnings Yield 1.0%)
[Growth] Growth Spread = +45.8% (Analyst 60.9% - Implied 15.1%)